The pharmaceutical microbiology testing service at Aurigene is supported by BSL-2 compliant lab and a dedicated in vivo facility for bacterial and fungal infection murine disease models. Our team has collaborated on numerous anti-bacterial and anti-fungal agent discovery projects with innovator pharma companies. We have a dedicated team of scientists and allied staff with vast experience in anti-infective drug discovery projects. We have established in vitro assays and in vivo murine efficacy models.
We also support generic product filings through bioequivalance studies of in vitro time-kill kinetics against reference drug.
Submissions to the US FDA
Highly qualified & experienced scientists
Audited by the US FDA with Zero 483 in 2019
BSL-2 compliant microbiology lab
Wide range of infectious models & microbiology assay capabilities
JUNE 28, 2022
An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...
Read MoreThe pharma industry is evolving and a demand for integrated CDMOs, which can help accelerating innovations, is part of the evolution....
Read MoreBacked by our strong chemistry, we enable “Finger-print” protein structure and functional characterization for proteins from naked proteins to hyperglycosylated or derivatized proteins. ...
Read MoreIntroduction: A fixed dose combination (FDC) includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. Fixed dose combination (FDC) product is expected to provide below advantages: Improved medication compliance by reducing the pill burden of patients. To achieve synergistic activity If combinations include doses of each drug...
Read More2016
Carbon monoxide gas and ligand-free conditions were developed for the synthesis of 2-hydroxy-3-alkyl-2-phenyl-2,3-dihydroquinazolin4(1H)-one via catalytic carbonylation with molybdenum hexacarbonyl as an efficient carbonylating agent for the three-component reaction of isatoic anhydride, amine, iodobenzene. Mo(CO)6 is a solid carbon monoxide source. The quinazoli...
Read More2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read MoreYou are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.